Equities

Nippon Chemiphar Co Ltd

4539:TYO

Nippon Chemiphar Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,602.00
  • Today's Change-5.00 / -0.31%
  • Shares traded2.60k
  • 1 Year change-16.39%
  • Beta0.7454
Data delayed at least 20 minutes, as of Jul 05 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NIPPON CHEMIPHAR CO., LTD. is a Japan-based company centered on ethical pharmaceutical products and mainly engaged in the pharmaceutical, health and beauty related businesses. The Company’s Pharmaceutical segment is engaged in the manufacture and sale of ethical pharmaceutical products. Other businesses include entrusted safety testing, healthcare and real estate leasing business. The Company mainly operates in Japan and Vietnam.

  • Revenue in JPY (TTM)30.75bn
  • Net income in JPY-180.00m
  • Incorporated1950
  • Employees887.00
  • Location
    Nippon Chemiphar Co Ltd2-2-3, Iwamoto-choCHIYODA-KU 101-0032JapanJPN
  • Phone+81 338631211
  • Fax+81 338645940
  • Websitehttps://www.chemiphar.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kubota Pharmaceutical Holdings Co Ltd39.74m-1.39bn4.17bn12.00--1.78--104.82-24.82-24.820.71141.580.01180.381526.893,312,000.00-41.32-36.51-45.53-39.4772.88---3,492.38-13,528.878.97--0.0555--383.24--26.11--24.38--
Renascience Inc194.17m-258.34m4.64bn4.00--2.89--23.90-20.32-20.3215.27126.400.089----48,541,250.00-11.84---12.49--85.31---133.05------0.1814--93.11--23.07------
Immuno-Biological Laboratories Co., Ltd.816.70m186.69m4.85bn57.0025.993.83--5.9420.0520.0587.69135.860.5350.93584.5314,328,090.0012.23-13.9714.68-16.3963.3457.7322.86-39.233.65--0.1572--2.780.8924164.44------
Delta-Fly Pharma Inc0.00-1.43bn5.02bn13.00--4.07-----197.24-197.240.00149.780.00----0.00-120.07-67.70-141.25-72.02-------877.69---243.150.00-------7.57---9.04--
Solasia Pharma KK408.00m-1.18bn6.00bn24.00--3.00--14.70-6.96-6.962.4010.010.14322.013.0617,000,000.00-41.50-48.57-53.67-58.8351.2371.01-289.71-300.891.68-400.000.2327---43.5014.1856.36------
COSMO BIO COMPANY, LIMITED9.46bn408.00m6.31bn155.0014.910.683611.110.667269.9469.941,620.671,525.810.84846.092.8761,000,000.003.805.624.546.7233.8237.404.486.235.15--0.002133.53-2.235.16-14.5111.20-8.0316.47
MEDRx Co Ltd22.57m-770.66m6.79bn22.00--3.18--300.65-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
NIPPON CHEMIPHAR CO., LTD.30.75bn-180.00m6.85bn887.00--0.31415.360.2227-49.89-49.898,520.205,115.780.62682.142.7034,665,160.00-0.36890.7482-0.52041.0825.1730.99-0.58871.131.53--0.479150.73-2.57-2.10-153.10--24.62-12.94
Perseus Proteomics Inc100.40m-1.10bn7.13bn25.00--4.13--71.01-93.74-93.748.52117.150.04713.358.554,016,080.00-51.85-41.34-54.94-43.4387.3391.72-1,100.04-891.2612.77--0.00--6.58-18.31-40.34--60.30--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.99bn109.00--1.11--1.72-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
K Pharma Inc500.00m-221.98m8.47bn15.00--2.95--16.94-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.85bn274.0080.910.73317.001.143.143.14222.97346.510.49712.092.5728,242,430.000.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
CanBas Co Ltd (Parent)0.00-1.09bn9.61bn12.00--3.21-----64.47-64.470.00166.100.00----0.00-43.91-65.86-45.99-79.11-------1,094.10----0.00-------45.41------
Kohjin Bio Co Ltd4.77bn384.98m9.61bn159.0020.372.3414.042.0192.3092.301,122.07802.50------30,000,600.00--------39.44--8.07--1.14--0.4249--0.5715---53.61------
Data as of Jul 05 2024. Currency figures normalised to Nippon Chemiphar Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.41%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 31 May 202424.00k0.56%
Nikko Asset Management Co., Ltd.as of 07 Jun 202411.60k0.27%
Daiwa Asset Management Co. Ltd.as of 31 May 202410.80k0.25%
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Jun 20244.90k0.12%
BlackRock Japan Co. Ltd.as of 06 Jun 20244.30k0.10%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 19 Feb 20241.90k0.05%
Asset Management One Co., Ltd.as of 06 Jun 20241.40k0.03%
Amundi Asset Management SA (Investment Management)as of 05 Jun 2024731.000.02%
Norinchukin Zenkyoren Asset Management Co., Ltd.as of 06 Jun 2024300.000.01%
Resona Asset Management Co., Ltd.as of 11 Dec 2023200.000.01%
More ▼
Data from 11 Dec 2023 - 27 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.